In the collaboration, Insitro will apply its proprietary platform, the Insitro Human (ISH) platform, to create disease models derived from induced pluripotent stem cells (iPSCs) for ALS and FTD. The platform applies machine learning, human genetics, and functional genomics to generate and optimize predictive in vitro models and accelerate therapeutic discovery and development. Bristol Myers Squibb will have the option to select a number of targets identified by Insitro to advance through clinical development and commercialization.

Insitro will receive $50 million in an upfront payment and will be eligible to receive an additional $20 million in near-term operational milestones, totaling more than $2 billion in discovery, development, regulatory, and commercial milestones in addition to clinical development as well as regulatory submissions and commercialization activities.

Bristol Myers Squibb advances cancer immunotherapy in Europe
The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Bristol Myers Squibb's nivolumab (Opdivo).

Bristol Myers Squibb licenses cell therapy candidate from Obsidian
Bristol Myers Squibb has exercised an option to an exclusive worldwide license to a cell therapy candidate based on Obsidian Therapeutics' cytoDrive technology.

Bristol Myers licenses immunotherapy from Dragonfly
Bristol Myers Squibb has paid $12 million to Dragonfly Therapeutics to license a fourth immunotherapy drug candidate from Dragonfly's TrinKet portfolio.

Dragonfly, Bristol Myers Squibb to develop immunotherapies
Dragonfly Therapeutics has entered into a research collaboration with Bristol Myers Squibb to discover and develop novel immunotherapies for multiple...